- Home
- OPTH vs TXMD Comparison
OPTH vs TXMD Comparison
Compare OPTH & TXMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | OPTH | TXMD |
|---|---|---|
| Founded | N/A | 2008 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.9M | 24.4M |
| IPO Year | 2024 | 2012 |
Fundamental Metrics
Financial Performance| Metric | OPTH | TXMD |
|---|---|---|
| Price | $4.78 | $2.01 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 23.4K | 17.8K |
| Earning Date | N/A | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 73.68 |
| EPS | N/A | ★ 0.02 |
| Revenue | N/A | ★ $1,761,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $100.50 |
| Revenue Growth | N/A | ★ 35.25 |
| 52 Week Low | $4.00 | $0.99 |
| 52 Week High | $5.45 | $2.95 |
Technical Indicators
Market Signals| Indicator | OPTH | TXMD |
|---|---|---|
| Relative Strength Index (RSI) | 49.38 | 42.74 |
| Support Level | $4.48 | $1.97 |
| Resistance Level | $5.08 | $2.11 |
| Average True Range (ATR) | 0.28 | 0.05 |
| MACD | -0.03 | -0.00 |
| Stochastic Oscillator | 34.78 | 5.58 |
Price Performance
Historical ComparisonAbout OPTH Optimi Health Corp. Common Shares
Optimi Health Corp operates in developing a vertically integrated Canadian functional mushroom brand that focuses on the health and wellness sector. The company has one reportable operating segment being that of the farming, processing, and distribution of raw mushroom biomass. It also intends to cultivate, extract, process, and distribute strains of fungi products at its facilities located in Princeton, British Columbia.
About TXMD TherapeuticsMD Inc.
TherapeuticsMD Inc is a pharmaceutical royalty company that owns and manages intellectual property, including trademarks and product rights, which are licensed to third-party pharmaceutical companies. The company generates revenue mainly through royalties and milestone payments from licensed products, including IMVEXXY, BIJUVA, and ANNOVERA, and does not directly manufacture or market pharmaceutical products.